Immunotherapy Plus Targeted Drug in First-line Kidney Cancer Immunotherapy Plus Targeted Drug in First-line Kidney Cancer
First-line immunotherapy with avelumab plus axitinib significantly improves progression-free survival in advanced kidney cancer over sunitinib, with no additional safety issues.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Health | Hematology | Immunotherapy | Kidney Cancer | Urology & Nephrology